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Purpose: Current guidelines support using in combination more than one class of long-acting
bronchodilator for COPD patients whose symptoms are not controlled by mono-therapy. This
2-week, multi-center (34 sites), randomized, modified-blind, parallel group study evaluated
the efficacy and safety of concomitant treatment with nebulized arformoterol (the formoter-
ol(R,R)-isomer) BID and tiotropium DPI QD.
Methods: COPD patients (mean FEV1 1.37 L, 45.4% predicted) were randomized to receive
mono-therapy (either arformoterol 15 mg BID [nZ 76] or tiotropium 18 mg QD [nZ 80]), or
combined therapy (sequential dosing of arformoterol 15 mg BID and tiotropium 18 mg QD
[nZ 78]). Changes in pulmonary function, dyspnea, and rescue levalbuterol use were evalu-
ated, as were safety outcomes.
Results: Mean FEV1AUC0e24 (the primary endpoint) improved similarly from baseline for arfor-
moterol (0.10 L) and tiotropium (0.08 L) treatment groups and greater for the combined
therapy group (0.22 L; all p-values <0.005). Peak FEV1, peak FVC, 24-h trough FEV1, and inspi-
ratory capacity also improved similarly for the mono-therapies and greatest for the combined
therapy. Dyspnea (mean transition dyspnea index) improved similarly for arformoterol (þ2.3)
and tiotropium (þ1.8) and greatest with combined therapy (þ3.1; p-values <0.05).24528 (data has been submitted; not yet posted).
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Arformoterol plus tiotropium for treating COPD 517Levalbuterol use decreased for all treatment groups (range 1.8 to 2.5 actuations/day). All
treatments had similar frequency of adverse events.
Conclusion: In this study, the combination of nebulized arformoterol 15 mg BID plus tiotropium
18 mg DPI QD was the most effective in improving pulmonary function and disease symptoms.
Mono-therapy improvement with arformoterol or tiotropium was similar. All three treatments
were well tolerated.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by airway flow obstruction that is poorly reversible
and is clinically characterized as either chronic bronchitis
or emphysema.1e3 Worldwide, COPD is one of the most
prevalent non-infectious diseases in the world and is the
fourth leading cause of death in the United States. It will
become the third leading cause of death worldwide by
2020.1e3 The health and cost burden of COPD is even more
substantial as it contributes to other serious comorbidities
including osteoporosis, fractures, respiratory infections,
lung cancer, and cardiovascular disease.4,5
Evidence-based guidelines recommend the use of long-
acting bronchodilators for maintenance treatment of COPD
in patients with moderate to very severe disease.1e3 In
general, two classes of long-acting bronchodilators are
available for treating COPD: the long-acting b2-agonists
(LABAs) such as salmeterol, formoterol, and arformoterol
(the (R,R)-formoterol isomer) which act for 12 h,6e10 and
the anticholinergic tiotropium which acts for 24 h.11e14
Racemic formoterol, arformoterol and tiotropium all
improve lung function with an onset of bronchodilation
within 2 h, improve quality of life, are well toler-
ated,6,7,12e20 and are associated with little clinically
meaningful tolerance.8,12,14,16,19
In the United States, currently available LABAs are
administered via dry powdered inhalers (DPI) or by nebuli-
zation. Some patients with COPD, particularly the elderly
and those with limited manual coordination or compro-
mised lung function, may have difficulty using single breath
hand-held inhalers resulting in ineffective respiratory
delivery of aerosolized medication.21e25 Nebulized formu-
lations of racemic formoterol and arformoterol, which
obviate technical difficulties in the use of hand-held
inhalers, are approved for the long-term maintenance
treatment of bronchoconstriction in COPD.6,8
Current guidelines recommend using the combination of
more than one class of long-acting bronchodilator for
patients whose symptoms are not controlled by broncho-
dilator mono-therapy.2,3,26 Previous studies have reported
that combined therapy with racemic formoterol and tio-
tropium is effective and safe in treating COPD patients and
results in greater improvement in airway function
compared with either mono-therapy alone.20,27e32 Although
arformoterol and racemic formoterol have the same bron-
chodilator moiety (the R,R-isomer), the two drugs differ
from one another in formulation, the presence of the
S,S-isomer, salts, excipients, and dosing amounts raising
the possibility that these drugs might have different effi-
cacy and safety profiles. This randomized double-blindstudy compared pulmonary function and symptom
improvement among patients treated with arformoterol
mono-therapy, tiotropium mono-therapy, and both thera-
pies combined, and tested the hypothesis that the
combined therapy would afford significantly greater effi-
cacy than either single-therapy.
Methods
This was a 2-week, prospective, multi-center (34 sites),
randomized, modified-blind, double dummy, parallel group
study designed to evaluate the efficacy and safety of the
combination of arformoterol 15 mg BID and tiotropium 18 mg
QD (dosed sequentially) versus the individual mono-thera-
pies in the treatment of COPD patients. The study was
conducted according to the principles established by the
Declaration of Helsinki.33 Appropriate Institutional Review
boards approved the protocol and written informed consent
was obtained from the patients.
Study patients
Of 429 patients screened, 235 were randomized to treat-
ment and 234 received at least one dose of study medica-
tion (intent-to-treat population [ITT]) (Fig. 1). All patients
had non-asthmatic COPD (including emphysema and/or
chronic bronchitis). Eligible patients were at least 45 years
of age had a 15 pack-year history of smoking, and had
a breathlessness severity based on Medical Research
Council Dyspnea Score 2.34 They also were required to
have a pre-bronchodilator baseline pulmonary function of
FEV1 >0.7 L, FEV1/FVC ratio of 70%, and FEV1 65% pre-
dicted. Patients were excluded if they had life-threatening
or unstable respiratory status within 30 days of the
screening visit. Patients who changed their prescribed dose
or type of COPD medication within 14 days prior to
screening or who had ever used tiotropium bromide inha-
lation powder were excluded.
During the study period, the use of LABAs or long- or
short-acting anticholinergic bronchodilators (except for the
study medication) was prohibited. Use of oral and inhaled
corticosteroids was allowed as long as patients were on
a stable dosing regimen for at least 14 days prior to study
entry that was maintained throughout the study. Patients
were required to withhold oral corticosteroids for at least
24 h prior to pulmonary function testing. Leukotriene
modifiers and methylxanthines were not allowed for at
least 7 days prior to study entry. Levalbuterol MDI (Xope-
nex Sepracor Inc., Marlborough, MA) was supplied and
used as needed for rescue medications for acute
Figure 1 Patient disposition.
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throughout the trial. Patients were instructed to withhold
the use of rescue medication for 6 h prior to each clinic
visit.Study protocol
At the screening visit, baseline values were obtained for
COPD symptoms, Modified Medical Research Council (MMRC)
Dyspnea Scale, heart rate, vital signs, and pulmonary
function tests. Medical event calendars and medication logs
that were to be completed daily, and rescue medication
were also dispensed. The medication logs were used to
assess compliance by monitoring the number of UDV/DPI
doses taken.
Eligible patients were randomized to receive one of
three treatments for 14 days: nebulized arformoterol 15 mg
(Brovana, Sepracor Inc., Marlborough, MA) BID and
placebo DPI QD, nebulized placebo BID and tiotropium
18 mg (Spiriva HandiHaler Boehringer Ingelheim, Ridge-
field, CT) DPI QD, or nebulized arformoterol 15 mg BID and
tiotropium 18 mg DPI QD. The nebulized drug was adminis-
tered first using the PARI LC Plus nebulizer driven by the
Duraneb 3000 compressor (Pari: Pari Respiratory Equip-
ment Inc., Midlothian, VA) at a flow rate of 3.3 L/min fol-
lowed (within 5 min) by the DPI administration
(HandiHaler). The tiotropium and placebo DPI capsules
were identical in size and shape but differed in color. For
this reason, patients who had previously used tiotropium
were excluded (see above) and the DPI capsules were
dispensed and collected by an independent Study Drug
Coordinator who was not otherwise involved in the study
visits.
At week 0 and week 2, medical event calendars and
blood samples were collected and vital signs and heart
measurements analyzed. At week 0, spirometry was per-
formed pre-morning dose, immediately (within 5 min) andat 30 min, 1, 2, 4, 6, 8, 10, and 12 h post-first dose. After
the 12-h pulmonary function test patients self-administered
the evening dose of study medication. At week 2, serial
spirometry was also performed as at week 0, as well as
immediately (within 5 min) following the evening dose
(administered 12 h after the morning dose) and 12.5, 13,
14, 16, 23, and 24 h post-morning dose. Inspiratory capacity
was evaluated pre-dose and at 2 h post-morning dose at
week 0, and pre-dose and 2, 11, 14, and 24 h post-morning
dose at week 2. All inspiratory capacity measurements
were the mean of acceptable inspiratory capacity maneu-
vers, two of which were reproducible. Prior to an inspira-
tory capacity maneuver a patient had to have a stable
expiratory level for about 10 breaths. Once the stable level
was achieved, at the end of exhalation of a normal breath
the patient was asked to make a steady and full inhalation
at normal inspiratory flow rates until the lungs were
completely full, and then to exhale at a normal rate.
Trough FEV1 and trough inspiratory capacity measurements
were evaluated 24 h after the first (morning) dose of
a clinic visit.
All pulmonary function values used were the highest
among the three acceptable maneuvers. The Investigator
ensured that all spirometry was performed in accordance
with the American Thoracic Society/European Respiratory
Society Standardisation of Spirometry guidelines.35
Centralized over-reading of spirometry and inspiratory
capacity pulmonary function measures were used for
quality control.
At screening, the baseline dyspnea index (BDI)36 was
assessed prior to the first clinic dose, and at week 2 the
transition dyspnea index (TDI)36 was evaluated before first
morning dose. The baseline focal score (range 0e12) and
the transition focal score (range 9 to 9) were the sums of
the functional impairment, magnitude of task, and magni-
tude of effort scores.36 Higher scores indicate less dyspnea
at baseline (BDI) or greater improvement in dyspnea from
baseline (TDI).
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Based on previous findings,6,7 the study was designed to
detect a mean treatment difference of time normalized
FEV1AUC over 24 h (FEV1AUC0e24) (the primary endpoint) of
0.075 L with a standard deviation of 0.160 L when
comparing combined therapy with mono-therapy, using
a two-sided 5% significance level, following 2 weeks of
dosing for the primary comparison with 80% power. All
efficacy analyses were performed on the ITT population. All
statistical testing was 2-tailed and conducted at the 5%
significance level, unless otherwise indicated. The primary
comparison was between the arformoterol plus tiotropium
group versus tiotropium alone. The key secondary analysis
comparison was between the arformoterol plus tiotropium
group versus arformoterol alone. To control for multiple
comparisons, statistical tests of mean treatment group
differences were considered significant if the overall
treatment effect in the model was statistically significant
at the 5% level. Pulmonary function severity subgroup
analysis was performed post hoc by stratifying patients
according to the GOLD COPD guidelines2 (<30%, 30% to
<50%, and 50%, respectively). Pair-wise comparisons
between treatment groups were performed using least
square means (LS means) from the linear model with the
study baseline (or pre-dose where applicable) as a cova-
riate and the treatment group as a fixed effect.
Descriptive statistics were calculated by treatment for
baseline characteristics and each efficacy parameter.
Adverse events were summarized using counts and
percentages. All adverse events were coded using the
Medical Dictionary for Regulatory Activities (MedDRA).37 A
COPD exacerbation was pre-defined as an increase in
symptoms that necessitated any change in baseline medi-
cation other than bronchodilators (e.g. anti-inflammatory
agents, antibiotics, supplemental oxygen therapy, etc.) or
caused the patient to require additional medical attention
(hospitalization, emergency room visit, etc.).
Results
Of the 429 patients enrolled in this study, 235 were
randomized and 234 received at least one dose of study
medication (ITT population) (Fig. 1). Demographic and
baseline characteristics, including FEV1, FVC, and inspira-
tory capacity values, were similar among treatment groups
(Table 1). Of the patients in the ITT population, 94.4%
completed the 2-week study with similar rates of comple-
tion for all three treatment groups (Fig. 1). The most
common reason for discontinuation was the occurrence of
adverse events (nZ 5 [2.1%]) (Fig. 1). Approximately 97%
of patients among the treatment groups were compliant
with the therapies throughout the study.
Pulmonary function outcomes
FEV1 at each time point and time normalized FEV1AUC0e24,
improved from baseline for all treatment groups (Fig. 2a
and b; Table 2). The two mono-therapies had comparable
improvement for both FEV1 and FEV1AUC0e24 and the
combined treatment group had the greatest improvementafter 2 weeks of treatment. The greater improvement in
FEV1AUC0e24 (the primary endpoint) for the combined
therapy versus the mono-therapies was significant
(p < 0.001). Peak change in FEV1, changes in trough (at end
of dosing interval) FEV1, and peak change in FVC improved
significantly from baseline following all treatments
(Table 2). The mono-therapy groups improved to a similar
extent and the combined therapy group had the greatest
improvement. The greater increase in peak FEV1 for
combined therapy was significant versus either mono-ther-
apies (p < 0.005). The 150 mL improvement in trough FEV1
for the combined therapy was statistically significant versus
the tiotropiummono-therapy (pZ 0.002) but not significant
versus arformoterol mono-therapy (pZ 0.07). The 60 mL
mean improvement in peak FVC for the combined therapy
was numerically greater than that observed for either mono-
therapy (tiotropium 40 mL and arformoterol 48 mL),
a difference that reached statistical significance versus tio-
tropium (pZ 0.05) but not versus arformoterol (pZ 0.07).
The LS mean (SE) peak improvement in FEV1 from visit
pre-dose was similar for the three treatment groups
(0.19  0.02 L for arformoterol, 0.19  0.02 L for tio-
tropium and 0.22  0.02 L for the arformoterol plus
tiotropium).
Mean (SD) inspiratory capacity improved from baseline
2-h post-dosing for all three treatment groups, and the
greatest improvement was observed for the combined
therapy group (arformoterol, 0.20  0.32 L, tiotropium,
0.19  0.32 L, and arformoterol plus tiotropium,
0.29  0.39 L) (Fig. 3). At trough (the 24-h time point since
first dose of visit) the inspiratory capacity was significantly
increased from study baseline for the combined treatment
group and approached significance for the arformoterol
treatment group (Table 2). Improvement in trough inspira-
tory capacity for the combination therapy was significantly
greater than tiotropium mono-therapy (pZ 0.03) but not
arformoterol mono-therapy (pZ 0.21).Symptom responses: rescue medication use and
BDI/TDI
Between screening and randomization (pre-dose week 0)
about 80% of patients in all treatment groups used leval-
buterol MDI as rescue medication (Table 3). Baseline rescue
use averaged approximately 3 actuations per day and about
4.5 days per week. The use of levalbuterol MDI decreased
over the second week of treatment for all three treatment
groups by a mean of 1.8 actuations per day for the mono-
therapies and 2.5 actuations per day for the combined
therapy groups. Differences for combined therapy versus
mono-therapies were not statistically significant.
Dyspnea, as measured by TDI, improved from baseline
for all three treatment groups and to a significantly greater
extent for the combined treatment group (Table 4). The
majority of patients in the three treatment groups had an
improvement in TDI of 1 unit, the minimal clinically
important difference. The combined therapy group had
a greater proportion of patients with 1 unit improvement
in TDI compared with the other two therapy groups, and
this difference was statistically significant between the
combined and tiotropium therapies (95% CI 0.06, 0.35).
Table 1 Demographics and baseline characteristics (ITT).
Arformoterol
15 mg BID
(nZ 76)
Tiotropium
18 mg QD
(nZ 80)
Arformoterol 15 mg BID
plus tiotropium
18 mg QD (nZ 78)
Mean age, years (SD) 61.6 (8.4) 61.2 (9.5) 62.2 (7.6)
Male, n (%) 39 (51.3) 43 (53.8) 42 (53.8)
Race, n (%)
Caucasian 71 (93.4) 74 (92.5) 70 (89.7)
Black 5 (6.6) 6 (7.5) 7 (9.0)
Other 0 0 1 (1.3)
Current smoker, n (%) 49 (64.5) 54 (67.5) 39 (50)
Pack-years smoked
15 to <30 years, n (%) 4 (5.3) 5 (6.2) 10 (12.8)
30 years, n (%) 72 (94.7) 75 (93.8) 68 (87.2)
Corticosteroid users, n (%)a 16 (21.1) 21 (26.3) 16 (20.5)
MMRC dyspnea scale, mean (SD) 2.7 (0.6) 2.9 (0.7) 2.9 (0.6)
Mean FEV1, L (SD) 1.37 (0.46) 1.38 (0.46) 1.35 (0.41)
Mean percent predicted FEV1, L (SD) 45.4 (11.9) 45.7 (11.5) 44.9 (12.0)
Mean FEV1% reversibility (SD) 15.4 (10.0) 15.2 (10.8) 15.7 (13.3)
Mean FVC, L (SD) 2.69 (0.78) 2.70 (0.77) 2.60 (0.67)
Mean inspiratory capacity, L (SD) 2.01 (0.62) 1.98 (0.56) 1.92 (0.52)
a Indicates the percentage of patients started taking inhaled or systemic corticosteroids during the screening period.
Figure 2 (a) Mean change in FEV1 from study baseline at
week 2. (b) Mean change in time normalized FEV1AUC0e24 from
study baseline at week 2.
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outcomes stratified by patient’s baseline lung
function severity
Pulmonary results stratifiedbybaselinedisease severity (pre-
dose FEV1<50%predicted or50%predicted), demonstrated
that patients with lower baseline lung function had greater
improvement in all pulmonary lung function measures than
patients with higher baseline lung function (see Supple-
mental Tables 1, 2, and 3). The greater improvement in
pulmonary function measures for those patients with more
compromised baseline lung function (<50% FEV1 predicted)
was evident for both absolute (L) and relative (percentage)
improvements. Patients with <50% FEV1 predicted demon-
strated significant improvement for all five forced expiratory
measures evaluated for both the mono-therapies and
combined therapy groups. In contrast, patients with 50%
FEV1predictedhadno significant improvement in troughFEV1
for any therapy group, and FEV1AUC0e24 only demonstrated
improvement for the combined therapy group.
The use of rescue medications decreased for both
disease severity groups (Supplemental Table 4). Both
subsets of patients had improved dyspnea following any of
the three therapies (Supplemental Table 4). Patients with
<50% predicted FEV1 at baseline treated with the combined
therapy had significantly greater improvement in TDI (3.5
units) than those treated with either arformoterol (2.3
units) or tiotropium (1.6 units) (Supplemental Table 5).
Safety
Adverse events were infrequent with similar occurrence
among the three treatment groups (Table 5). Both COPD
exacerbations and cardiovascular adverse events were
observed in only a small proportion of patients (between
Table 2 Change in spirometry measurements from baseline at week 2.
Arformoterol
15 mg BID (nZ 76)
Tiotropium
18 mg QD (nZ 80)
Arformoterol 15 mg
BID plus tiotropium
18 mg QD (nZ 78)
Change in FEV1AUC0e24, (L),
mean (SD) (95% CI)
0.10 (0.21) (0.05, 0.16) 0.08 (0.20) (0.04, 0.12) 0.22 (0.20) (0.18, 0.27)
Difference between combined
therapy and mono-therapies,
(L), LS mean (95% CI; p-value)
0.12 (0.05, 0.18; p<0.001) 0.14 (0.08, 0.20; p<0.001)
Peak change in FEV1 over 12 h,
(L), mean (SD) (95% CI)
0.27 (0.21) (0.22, 0.32) 0.27 (0.23) (0.21, 0.32) 0.38 (0.22) (0.33, 0.43)
Difference between combined
therapy and mono- therapies,
(L), LS mean (95% CI; p-value)
0.11 (0.03, 0.18; pZ0.004) 0.11 (0.04, 0.19; pZ0.002)
Change in trough FEV1 (L), mean
(SD) (95% CI)a
0.09 (0.23) (0.03, 0.14) 0.08 (0.21) (0.03, 0.13) 0.15 (0.22) (0.10, 0.21)
Difference between combined
therapy and mono- therapies,
(L), LS mean (95% CI; p-value)
0.07 (0.01, 0.14; pZ0.07) 0.07 (0.0, 0.14; pZ0.05)
Peak change in FVC over 12 h (L),
mean (SD) (95% CI)
0.48 (0.37) (0.39, 0.57) 0.40 (0.34) (0.32, 0.48) 0.60 (0.43) (0.50, 0.70)
Difference between combined
therapy and mono- therapies,
(L), LS mean (95% CI; p-value)
0.12 (0.01, 0.25; pZ0.07) 0.20 (0.08, 0.33; pZ0.002)
Change in trough inspiratory
capacity (L), mean (SD) (95% CI)a
0.07 (0.30) (0.00, 0.15) 0.02 (0.29) (-0.05, 0.09) 0.15 (0.36) (0.07, 0.24)
Difference in trough FEV1 between
combined therapy and mono-
therapies (L), LS mean (95% CI; p-value)
0.07 (0.04, 0.18; pZ0.21) 0.12 (0.02, 0.23; pZ0.03)
a Trough is defined as the given pulmonary function variable measured at the 24-h time point after morning dose.
Arformoterol plus tiotropium for treating COPD 5210 and 3.9%). Only one patient (arformoterol 15 mg) reported
a serious adverse event (small intestinal obstruction).
Discussion
The combined use of bronchodilators with different phar-
macological mechanisms of action for COPD patients is
supported by current evidence based guidelines.2,3,26 This
study investigated the efficacy and safety of the combina-
tion of two long-acting bronchodilators: arformoterol
administered via nebulizer and tiotropium administered as
a DPI. In particular, it compared efficacy between the two
mono-therapies and evaluated whether the combined useFigure 3 Change in inspiratory capacity from study baseline
at week 2.of these drugs resulted in greater pulmonary improvement
than either single-agent alone. This is the first reported
study to compare pulmonary function and symptoms
improvement in COPD patients treated with a nebulized
LABA (arformoterol) mono-therapy, tiotropium mono-
therapy, and both therapies combined. It is also unique in
that it presents data on how COPD patients with differing
disease severity respond to arformoterol and tiotropium
monotherapies, as well as the LABA/LAMA (arformoterol/
tiotropium) combined therapy.
All three therapies demonstrated clinically meaningful
improvement in pulmonary function from baseline after
2 weeks of treatment. However, the combined use of
arformoterol and tiotropium was associated with signifi-
cantly larger increases in time normalized FEV1 over a 24-h
period and peak change in FEV1 than either arformoterol or
tiotropium mono-therapies. Trough FEV1 (24 h post-dose at
week 2), another efficacy measure for a maintenance
bronchodilator, improved for all three treatment groups
indicating that bronchodilation was maintained throughout
the dosing interval. The combination therapy resulted in
a 70 mL greater improvement in trough FEV1 than either
mono-therapy. These findings are consistent with previous
reports that investigated the combination of tiotropium
with racemic formoterol20,27,28,30,31,38 which found that the
combination of tiotropium and racemic formoterol resulted
in greater improvement in pulmonary function than either
single-agent alone. On the other hand, another study that
examined the effect of adding either salmeterol alone or
Table 3 Daily rescue medication (levalbuterol) use.
Arformoterol
15 mg BID (nZ 76)
Tiotropium
18 mg QD (nZ 80)
Arformoterol 15 mg
BID plus tiotropium
18 mg QD (nZ 78)
Baseline (prior to first dose week 0)
Used levalbuterol, n (%) 61 (80.3) 64 (80.0) 65 (83.3)
Number of actuations per day, mean (SD) 3.2 (3.2) 2.8 (2.8) 3.1 (2.7)
Number of days per week, mean (SD) 4.4 (2.8) 4.3 (2.9) 4.6 (2.8)
Week 2 (change from baseline)
Used levalbuterol, n (%) 40 (52.6) 38 (47.5) 26 (33.3)
Number of actuations per day, mean (SD) 1.8 (2.2) 1.8 (2.8) 2.5 (2.3)
Number of days per week, mean (SD) 2.1 (2.6) 2.2 (2.7) 3.3 (3.0)
522 D.P. Tashkin et al.the salmeterol/fluticasone combination to tiotropium over
a 1-year treatment period failed to find an additive effect
of salmeterol when added to tiotropium on trough FEV1.
38
In this study, the improvement in FEV1 after arformo-
terol mono-therapy dosing differed between the morning
and evening dose. The mean FEV1 improvement 2 h after
the morning dose and evening dose were approximately
213 mL and 182 mL, respectively. This temporal difference
in response has been reported for racemic formoterol
administered BID,31 and was suggested to reflect circadian
changes in the activity of the adrenergic system and vagal
system.27,31 The adrenergic system is most prominent
during the day and the parasympathetic system activity
increases during the night.39 The relative reduction in the
effect of tiotropium mono-therapy between 12 and 23 h
may also result from this circadian nocturnal drop in airway
function and the waning effect of tiotropium that dosed
once daily in the morning.40
Inspiratory capacity and dyspnea, both reflections of
hyperinflation, improved in this study after dosing for all
three treatments and to a greater extent in the combined
treatment group. Similar to the findings for trough FEV1,
the fact that trough inspiratory capacity (at the 24-h time
point at week 2) was greater than baseline indicates that
the effect of the three therapies (arformoterol 15 mg BID,
tiotropium 18 mg QD, and arformoterol 15 mg BID plus tio-
tropium 18 mg QD) on this outcome persisted for 24 h. In
contrast to prior reports that examined the combination of
tiotropium and racemic formoterol,27,20 this study found
that the combined effect of tiotropium and arformoterol on
trough inspiratory capacity was significantly greater than
that of tiotropium alone. Dyspnea improved by more than 1
unit (the MCID)41 for all three therapies and greatest (mean
TDI; þ3.1 units) for the combined therapy. Rescue short-Table 4 Baseline dyspnea (BDI)/transitional dyspnea index (TD
Arformotero
15 mg BID (n
BDI, mean (SD) 5.8 (2.0)
TDI, mean (SD) 2.3 (2.4)
Difference between combined therapy and
mono-therapies (L), LS mean (95% CI)
0.9 (0.03, 1.
Patients with change 1 unit, n (%) 50 (66.7)acting b2-agonist use decreased with all three therapies and
again to a slightly greater extent with combination therapy
than either mono-therapy. These findings are consistent
with earlier reports that found that treatment with racemic
formoterol, tiotropium,17,20,32,42,43,44 or the combination of
racemic formoterol plus tiotropium20 improved dyspnea20
and reduced rescue racemic albuterol use.17,20,32,42e44
Only a few prior publications have addressed the question
how patients with differing severity of baseline COPD
respond to therapy.7,45 In this study, stratified analysis of the
response of patients based on baseline GOLD guideline clas-
sification of disease severity (e.g. very severe and severe:
<50% predicted FEV1; and moderate:50% predicted FEV1)3
demonstrated that patients with more severe COPD had
greater airway improvement than those with moderate
COPD. Pre-dose (trough) andpost-dose FEV1 values increased
more for patients with more severe COPD compared with
those with moderate disease. Moreover, trough inspiratory
capacity increased only for patients with more severe
disease. Improvements in dyspnea (TDI), in contrast, were
similar between disease severity groups. These findings
suggest that disease severity influences the degree of bron-
chodilator improvements in forcedexpiratorymaneuvers and
inspiratory capacity. These findings are in contrast to a prior
study that found that patients with very severe COPD (GOLD
stage III and IV) had less responsiveness to large doses of the
short-acting b2-agonist racemic albuterol plus ipratropium
bromide than patients with moderate COPD.46 The differ-
ence between these studies may reflect differences in
experimental design and/or medication studied.
This study supports the recommendations of the GOLD
guidelines3 that advise the combination of two different
classes of long-acting bronchodilators for treatment of
patients with moderate to severe COPD. The administrationI) at week 2 for the ITT population.
l
Z 76)
Tiotropium
18 mg QD (nZ 80)
Arformoterol 15 mg
BID plus tiotropium
18 mg QD (nZ 78)
5.8 (1.9) 5.5 (2.1)
1.8 (2.8) 3.1 (2.4)
7) 1.3 (0.5, 2.2)
44 (57.1) 60 (77.9)
Table 5 Adverse events.
Arformoterol
15 mg BID (nZ 76)
Tiotropium
18 mg QD (nZ 80)
Arformoterol 15 mg
BID plus tiotropium
18 mg QD (nZ 78)
Any adverse event, n (%) 19 (25.0) 22 (27.5) 24 (30.8)
COPD exacerbations 3 (3.9) 0 0
Overall cardiovascular adverse events, n (%) 2 (2.6) 1 (1.3) 0
Discontinued due to adverse events, n (%) 2 (2.6) 1 (1.3) 2 (2.6)
Serious adverse events, n (%) 1 (1.3) 0 0
Arformoterol plus tiotropium for treating COPD 523of tiotropium QD plus arformoterol BID resulted in signifi-
cantly superior bronchodilation to either agent alone as
well as significantly greater improvement in symptom
relief. Tiotropium and arformoterol mono-therapy were
equally efficacious and improved dyspnea and reduced
rescue medication use to a similar extent, consistent with
prior studies that compared tiotropium and racemic for-
moterol.28,31,47 This is in contrast to prior literature that
evaluated the LABA salmeterol and tiotropium mono-ther-
apies which suggested that tiotropium exhibited advan-
tages over salmeterol in treating COPD patients.14,18,44,48
COPD subjects with more severe degree of airway function
compromise had greater improvement in lung function and
symptoms than those with moderate impairment. Long-
term studies are needed to understand the potential
impact of arformoterol and tiotropium combined therapy
on long-term health outcomes, such as COPD exacerbations
and hospitalizations. In addition, investigations of existing
and emerging therapies are needed to determine optimal
individual treatment for patients affected by different
subtypes and severity of disease.
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